EA202193189A1 - Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий - Google Patents

Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий

Info

Publication number
EA202193189A1
EA202193189A1 EA202193189A EA202193189A EA202193189A1 EA 202193189 A1 EA202193189 A1 EA 202193189A1 EA 202193189 A EA202193189 A EA 202193189A EA 202193189 A EA202193189 A EA 202193189A EA 202193189 A1 EA202193189 A1 EA 202193189A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complement system
paraproteinemic
antagonist
neuropathy
treatment
Prior art date
Application number
EA202193189A
Other languages
English (en)
Russian (ru)
Inventor
Кристоф Бланхетот
Кевин Баддинг
Эрик Хак
Карен Силанс
Инге Ван Дер Валле
Людо Ван Дер Пол
Петер Боросс
Original Assignee
Ардженкс Бвба
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардженкс Бвба filed Critical Ардженкс Бвба
Publication of EA202193189A1 publication Critical patent/EA202193189A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202193189A 2019-05-21 2020-05-21 Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий EA202193189A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1907153.9A GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy
PCT/EP2020/064234 WO2020234432A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies

Publications (1)

Publication Number Publication Date
EA202193189A1 true EA202193189A1 (ru) 2022-03-11

Family

ID=67385155

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193189A EA202193189A1 (ru) 2019-05-21 2020-05-21 Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий

Country Status (21)

Country Link
EP (2) EP4570316A3 (cg-RX-API-DMAC7.html)
JP (3) JP7607590B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010505A (cg-RX-API-DMAC7.html)
CN (2) CN114269382B (cg-RX-API-DMAC7.html)
AU (2) AU2020279543B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138401A1 (cg-RX-API-DMAC7.html)
DK (1) DK3972643T3 (cg-RX-API-DMAC7.html)
EA (1) EA202193189A1 (cg-RX-API-DMAC7.html)
ES (1) ES3035736T3 (cg-RX-API-DMAC7.html)
FI (1) FI3972643T3 (cg-RX-API-DMAC7.html)
GB (1) GB2584105B (cg-RX-API-DMAC7.html)
HU (1) HUE072743T2 (cg-RX-API-DMAC7.html)
IL (1) IL288010A (cg-RX-API-DMAC7.html)
LT (1) LT3972643T (cg-RX-API-DMAC7.html)
MA (1) MA71752A (cg-RX-API-DMAC7.html)
MX (2) MX2021014170A (cg-RX-API-DMAC7.html)
PL (1) PL3972643T3 (cg-RX-API-DMAC7.html)
PT (1) PT3972643T (cg-RX-API-DMAC7.html)
SG (1) SG11202112232YA (cg-RX-API-DMAC7.html)
WO (1) WO2020234432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
CN117597353A (zh) * 2021-03-18 2024-02-23 艾菲洛之克公司 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
US20240166692A1 (en) * 2021-03-18 2024-05-23 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
MX2024008273A (es) * 2021-12-30 2024-07-19 Annexon Inc Composiciones y metodos para el tratamiento de la enfermedad de huntington.
MA71448A (fr) * 2022-07-14 2025-04-30 argenx BV Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)
EP4676952A2 (en) * 2023-03-07 2026-01-14 The Cleveland Clinic Foundation Human complement component 2 binding molecules
WO2025146509A1 (en) * 2024-01-05 2025-07-10 argenx BV Methods of treating multifocal motor neuropathy (mmn)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2008030505A2 (en) * 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
PL2753636T3 (pl) * 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
CN102949719A (zh) * 2012-04-28 2013-03-06 上海市徐汇区中心医院 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
US9944717B2 (en) 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof
WO2015089368A2 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
CN108026134A (zh) * 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
WO2017196960A1 (en) * 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
SG11201907583TA (en) * 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
CA3078971A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania

Also Published As

Publication number Publication date
CN118021970A (zh) 2024-05-14
PL3972643T3 (pl) 2025-09-08
JP2022533705A (ja) 2022-07-25
CN114269382B (zh) 2024-02-23
AU2026205212A1 (en) 2026-07-23
EP4570316A3 (en) 2025-08-13
MX2021014170A (es) 2022-01-04
PT3972643T (pt) 2025-07-15
NZ781789A (en) 2025-03-28
EP4570316A2 (en) 2025-06-18
LT3972643T (lt) 2025-07-10
JP7607590B2 (ja) 2024-12-27
EP3972643A1 (en) 2022-03-30
JP2025041724A (ja) 2025-03-26
ES3035736T3 (en) 2025-09-08
AU2020279543B2 (en) 2026-06-04
HUE072743T2 (hu) 2025-12-28
GB2584105A (en) 2020-11-25
GB201907153D0 (en) 2019-07-03
KR20220010505A (ko) 2022-01-25
AU2020279543A1 (en) 2021-11-25
WO2020234432A1 (en) 2020-11-26
CN114269382A (zh) 2022-04-01
MA71752A (fr) 2025-05-30
JP2025038109A (ja) 2025-03-18
CA3138401A1 (en) 2020-11-26
SG11202112232YA (en) 2021-12-30
DK3972643T3 (da) 2025-07-21
IL288010A (en) 2022-01-01
US20250066460A1 (en) 2025-02-27
EP3972643B1 (en) 2025-05-14
BR112021023198A2 (pt) 2022-01-04
FI3972643T3 (fi) 2025-07-16
MX2025014486A (es) 2026-01-07
GB2584105B (en) 2023-08-02

Similar Documents

Publication Publication Date Title
EP4570316A3 (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
BR112022004474A8 (pt) Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201891570A1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта
EA201891495A1 (ru) Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
CY1124238T1 (el) Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης
PH12022500028A1 (en) Methods for treating or preventing sars-cov-2 infections and covid -19 with anti-sars-cov-2 spike glycoprotein antibodies
IL285627A (en) Systems and methods for the treatment of symptoms associated with migraines
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AR107983A1 (es) Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1
EP4298128A4 (en) Methods of preventing, alleviating or treating tumors
MX2022015677A (es) Metodos para tratar la alergia usando anticuerpos anti-bet v 1.
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
BR112022010934A2 (pt) Métodos para tratar copd administrando um antagonista de il-33
MX2022004164A (es) Anticuerpos anti-flt-1 para tratar displasia broncopulmonar.
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий
EA201290851A1 (ru) Способы и композиции для лечения или предупреждения симптомов гормональных изменений
MX2023009272A (es) Métodos para tratar los glioblastomas con sepiapterina.
GEAP202416461A (en) Actrii proteins and uses thereof
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.